Suven Life Sciences Limited, on Monday, has announced that it has got US patent for two new chemical entities (NCEs) for the treatment of neurological diseases.

In a statement to the BSE, the Hyderabad-based biopharmaceutical company said that U. S. patent office has approved two molecules in the central nervous system
(CNS) arena developed by the company for the treatment of cognitive disorders and these patents are applicable till 2022 and 2024.